Henry Han

What is current guideline-recommended medical therapy for #HFrEF? #ESCCongress @escardio

🚨The latest alarming look at real-world use of #GDMTworks for #HF 🇺🇸Optum database 2020-2023 -Enormous gaps in #GDMT use, across the LVEF spectrum -When initiated, usually only after a substantial delay 🤯🤯🤯 @DCRINews @JAHA_AHA ahajournals.org/doi/10.1161/JA…

Universal healthcare can reduce disparities. In the NHFA, Non-White HF patients have ⬆️ more specialist care ⬆️ GDMT use ⬇️mortality vs White patients #HeartFailure #CardioTwitter @slumberbell @HanCardiomd @GianluSava @hvanspall @DrMarthaGulati @gbiondizoccai @AntonioJordanR

9e) Why does delayed ATTR-CM dx persist despite approved #DMTs #tafamidis #acoramidis #vutrisiran? In this #VHA cohort >25% waited >3yr. AF, CAD, and CKD ⬆️ odds of delay ➡️anchoring bias may mask amyloidosis as “garden variety” #HFpEF.

Excited to share a new accredited tweetorial from @cardiomet_ce! Latest 2026 data on #ATTR-CM, focusing on diagnosis and management with #TTR stabilizers. @academiccme cardiometabolic-ce.com/attr9/

12a) So new data continue to ➡️#ATTRCM is often dx'd late, on avg ~1y symptom onset➡️therapy. ~13% of #HFpEF pts may have 🫀 amyloidosis, yet ♀️remain underrepresented in ATTR-CM cohorts. Are current diagnostic thresholds (e.g., IVSD ≥12 mm) missing female phenotypes?

7a) 2019–2022: incidence of overall #ATTR ⬆️~7–9%, clearly driven by #ATTR-CM (~10% ⬆️). This study ➡️22–26% ⬆️ overall ATTR prevalence over just 3y. #ATTRCM accounts for most of the ⬆️. Trends were consistent across narrow vs broad defs, tho absolute numbers differed alot.

1) Welcome to a new #accredited #tweetorial and an update on #ATTR_CM examining the most interesting & important data published so far in 2026! We welcome new expert faculty Han Naung Tun (aka Henry Han) MD @HanCardiomd, #cardiologist Physician-Sci & Researcher #HeartFailure

14d) Looking deeper into #ATTRibute_CM: the 4-step hierarchical primary endpoint (#ACM, #CVH, #NTproBNP, #6MWD) favored #acoramidis at 30mos (win ratio 1.8; p<0.0001). RRR: ACM ↓23% (HR 0.77), CVH ↓50% (p<0.0001; NNT=5/yr).

11a) Take a look at 🔓 pubmed.ncbi.nlm.nih.gov/41528278/. 555 pts (315 ♀️), mean ± SD age 68.7±11.0. 3/5 had bilat sx. Biopsy procedure proved safe. Amyloid was ID'd in 216 (39%) cases (51% of ♂️ and 30% of ♀️ pts), more frequently in tenosynovial than transverse carpal ligament biopsies.

21) And for now, point your 🖱️to cardiometabolic-ce.com/attr9/ and claim your 🆓ONE HOUR CE/#CME! Many thanks to our expert author, @HanCardiomd! #MedEd

3a) #ATTR #amyloidosis is a progressive and life-threatening disease caused by misfolded #transthyretin #TTR protein deposition. Do we have updated epidemiology data for ATTR amyloidosis? (Figure from 🔓 pubmed.ncbi.nlm.nih.gov/34841715/ )

Thx @EricTopol for highlighting our hybrid cardio-onc/CHIP clinic @Yale. Clonal hematopoiesis is reshaping how we think about CV🫀risk, including in cancer patients (CH=2-3x more prevalent); excited to build clinical models that bring these discoveries to patients w/@KnowingAlok!

A deliberate erosion of the scientific enterprise begins by eroding the workforce. In 2025 alone, the U.S. lost more than 10,000 STEM Ph.D.s across 14 federal agencies. The brain drain is real.

☕️ How does #caffeine affect #cardiometabolic health? Our new review discusses current evidence, controversies & clinical implications of caffeine consumption for CV & metabolic health 👉doi.org/10.1093/nutrit… @drpablocorral @pabeda1 @HanCardiomd @SABOURETCardio #CardioX

ML cluster analysis on outcome trajectories in hospitalized #HFpEF 📍Cluster 1: Younger pts with de novo HF, fewer comorbidities, preserved renal function, lower BNP & NLR → lowest risk (reference group) 📍Cluster 2 (elderly women with HTN + AF) → ~3× higher risk vs Cluster 1 (HR 2.9; 95% CI 1.7–5.2; P < .001). 📍Cluster 3 (worsening HF, ↑NYHA, renal dysfunction, anemia, ↑BNP/NLR) → ~5× higher risk (HR 4.8; 95% CI 2.7–8.4; P < .001). 📍NYHA class & NLR were key predictors; results consistent during the 3-month vulnerable period #EJHF @ESC_Journals @EJHFEiC

#COBRRA Trial (n=2760) comparing #apixaban vs #rivaroxaban for acute PE or proximal DVT over 3 months 📍Clinically relevant bleeding: 3.3% with apixaban vs 7.1% with rivaroxaban (RR 0.46; 95% CI 0.33–0.65; P < .001). 📍All-cause death: 0.1% vs 0.3% (RR 0.25; 95% CI 0.03–2.26). 📍Serious non-bleeding AEs: 2.7% (apixaban) vs 2.2% (rivaroxaban)

Heart failure with preserved ejection fraction beyond the heart: exploring the heart–liver–pancreas axis academic.oup.com/eschf/article/… #ESCHF @ESC_Journals

@AJIAorg @Stanford mtg brought phys-scientists, AI leaders, industry innovators & investors to discuss the future of biomedical discovery. From enterpreneurship →starting a lab→AI in medicine→academic-industry partnerships→next-gen investigators, there's great promise.🧵